Document Detail

Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin's disease.
MedLine Citation:
PMID:  21559977     Owner:  NLM     Status:  Publisher    
AIM: To evaluate the role of postchemotherapy FDG PET and compare it with other predictive factors in paediatric Hodgkin's disease (HD). MATERIALS AND METHODS: In this retrospective study, 98 paediatric patients with HD (enrolled in eight Italian centres) were analysed. Their mean age was 13.8 years (range 5-19 years). A PET scan was performed at the end of chemotherapy and reported as positive or negative on the basis of visual and/or semiquantitative analysis. True outcome was defined as remission or disease on the basis of combined criteria (clinical, instrumental and/or histological) with a mean follow-up period of 25 months. Statistical analyses were performed for the postchemotherapy PET results and other potential predictive factors (age cut-off, stage, presence of bulky masses and therapeutic group) with respect to patient outcome and progression-free survival (PFS). RESULTS: Overall the patients had a mean PFS of 23.5 months (range 4-46 months): 87 achieved remission (88.8%) and 11 showed disease. Of the 98 patients, 17 were positive on postchemotherapy PET . Seven patients (41%) showed disease during follow-up, and relapse occurred in only four out of the 81 patients who were negative on PET (p = 0.0001). Kaplan-Meier analysis demonstrated significant correlations between PFS and the postchemotherapy PET result (p = 0.0001) and a cut-off age at diagnosis of 13.3 years (p = 0.0337), whereas disease stage (p = 0.7404), therapeutic group (p = 0.5240) and presence of bulky masses (p = 0.2208) were not significantly correlated with PFS. Multivariate analysis confirmed a statistically significant correlation with PFS only for the postchemotherapy PET findings (p = 0.0009). CONCLUSION: In paediatric HD, age at diagnosis and postchemotherapy PET results are the main predictors of patient outcome and PFS, with FDG PET being the only independent predictive factor for PFS.
Egesta Lopci; Roberta Burnelli; Luca Guerra; Angelina Cistaro; Arnoldo Piccardo; Pietro Zucchetta; Enrico Derenzini; Alessandra Todesco; Alberto Garaventa; Fabio Schumacher; Piero Farruggia; Salvatore Buffardi; Alessandra Sala; Fiorina Casale; Paolo Indolfi; Samanta Biondi; Andrea Pession; Stefano Fanti
Related Documents :
1322167 - Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small...
14707497 - Phase ii study of interferon gamma in malignant carcinoid tumors (e9292): a trial of th...
9679527 - A phase ii study of carboplatin, cisplatin, interferon-alpha, and tamoxifen for patient...
21486867 - Diffuse large b-cell lymphoma with involvement of the kidney: outcome and risk of centr...
19317257 - A retrospective analysis of twenty-eight borderline ovarian tumours in adolescent girls.
12682787 - Durable complete clinical responses in a phase i/ii trial using an autologous melanoma ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-5-11
Journal Detail:
Title:  European journal of nuclear medicine and molecular imaging     Volume:  -     ISSN:  1619-7089     ISO Abbreviation:  -     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-5-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101140988     Medline TA:  Eur J Nucl Med Mol Imaging     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Nuclear Medicine Department, University Hospital S. Orsola-Malpighi, Via Massarenti, 9, CAP 40138, Bologna, Italy,
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cell physiology rather than enzyme kinetics can determine the efficiency of cytochrome P450-catalyze...
Next Document:  Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with i...